Sangamo Therapeutics, Inc.SGMONASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank13
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-312.74%
↓ 90% vs avg
Percentile
P13
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-164.82%
Historical baseline
PeriodValueYoY Change
TTM-312.74%-102.9%
2024-154.13%-180.6%
2023-54.93%+67.7%
2022-169.97%-13.6%
2021-149.68%-42.8%
2020-104.80%-6.0%
2019-98.85%-11.6%
2018-88.56%+41.0%
2017-150.03%+58.8%
2016-364.51%-